Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...
Revenue for the three months ended September 30, 2025, was $216,000, compared to $72,000 for the same period in 2024. The ...
SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
CFO’S MESSAGE Calfrac generated Adjusted EBITDA of $48.5 million and net income of $4.3 million from continuing operations ...
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined ...
Accelsius recently secured strategic investment from Johnson Controls and introduced its NeuCool® MR250 system; pipeline of opportunities now ...
Both Ziihera plus Tevimbra and chemotherapy, and Ziihera plus chemotherapy demonstrated improvements in the key secondary endpoints of objective response rate (ORR) and duration of response (DoR) ...
Highlights: Commissioning and operations team fully mobilised to site at Kiniéro Gold Project as Robex prepares for first ...
Climate summit sees some progress on Global Goal on Adaptation; North-South divide mars talks despite early agenda adoption.
Third Quarter 2025 Financial Results Net revenue in the third quarter of 2025 increased 58% to $11.8 million, compared to $7.5 million in the third quarter of 2024. The increase was due to an increase ...
Commissioning and operations team fully mobilised to site at Kiniéro Gold Project as Robex prepares for first g ...
Prime Minister Mark Carney has revealed the second batch of potentially "nation-building" infrastructure projects to be ...